Reference Product Sample Abuses: Indian Firms Flag Concerns With FTC
Indian generic firms appear to be weighing in on controversy around brand name company tactics in the US to block access to reference products for bioequivalence testing – but generic firms may ultimately need legislation to resolve their concerns.
You may also be interested in...
Commissioner Gottlieb outlines several steps agency is taking – including potentially dropping requirement for shared REMS – to create more competitive generic marketplace.
FTC files second amicus brief saying use of risk management programs to impede generic competition could violate antitrust laws; commission launched an investigation of Celgene four years ago.
India’s national list of essential medicines 2022 features 34 additions, including insulin glargine, teneligliptin, lenalidomide, bedaquiline and montelukast, with price control expected to follow on these drugs.